As AAV‐FGF21 gene therapy have resulted in marked reductions in bodyweight and insulin resistance in HFD feeding and ob/ob mice,62 FGF21 can be a potential target to treat obesity and insulin resistance. The gene discussed is FGF21; the disease is obesity disorder.